GLP-1 drugs like Ozempic and Wegovy have rapidly moved from niche diabetes treatments to blockbuster weight loss injections, ...

The WHO issues its first official guidance on GLP-1 drugs for obesity treatment, as the disease affects over one billion ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health ...

According to last year’s National Food and Nutrition Society Survey, 31% of men and 68% of women in South Africa are ...

A similarly designed study in patients with both obesity and diabetes, published in Retina, also linked GLP-1 drugs to lower risk of AMD than seen with alternative therapies (15% reduced risk of dry ...

Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an ...

Pennsylvania has quietly moved to limit access next year to popular weight-loss drugs like Ozempic and Wegovy for residents ...

The World Health Organization issued new guidelines recommending the use of GLP-1 drugs for adults with obesity and called for action on manufacturing and affordability.

The World Health Organization (WHO) released its first-ever guideline on using GLP-1 medications to treat obesity.

A competitive drug market strongly encourages companies to best their rivals by developing the next generation of life-saving therapies.

Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is also fast nearing the $1 trillion market cap benchmark. The key driver of ...